Zentalis Pharmaceuticals (ZNTL) Expected to Announce Quarterly Earnings on Tuesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is expected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Zentalis Pharmaceuticals to post earnings of ($0.74) per share for the quarter.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $2.43 on Tuesday. Zentalis Pharmaceuticals has a twelve month low of $1.61 and a twelve month high of $18.07. The company’s fifty day simple moving average is $2.62 and its 200-day simple moving average is $3.10.

Insider Buying and Selling

In related news, insider Ingmar Bruns bought 20,000 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was bought at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the purchase, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jan Skvarka bought 60,000 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average price of $1.72 per share, with a total value of $103,200.00. Following the completion of the purchase, the director now directly owns 149,551 shares in the company, valued at $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Guggenheim cut their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Wells Fargo & Company lowered their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. UBS Group lowered their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. HC Wainwright lowered their price target on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. Finally, Wedbush restated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.